How does DBI's PB Ratio compare to its peers?

DBI is expensive based on its Price-To-Book Ratio (6.7x) compared to the peer average (0.8x).

How does DBI's PB Ratio compare vs other companies in the DE Biotechs Industry?

DBI is expensive based on its Price-To-Book Ratio (6.7x) compared to the European Biotechs industry average (2.5x).

What is DBI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate DBI's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of DBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate DBI's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Deutsche Biotech Innovativ DB:DBI Stock Report

Last Price

€5.05

Market Cap

€4.5m

7D

0%

1Y

-79.8%

Updated

24 Dec, 2023

Data

Company Financials

Deutsche Biotech Innovativ AG

DB:DBI Stock Report

Market Cap: €4.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DBI Stock Overview

Operates as a biotechnology company in Germany. More details

DBI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (€5M)

Makes less than USD$1m in revenue (€0)

Earnings have declined by 6.9% per year over past 5 years

Shares are highly illiquid

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Deutsche Biotech Innovativ AG Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€15.2m

bioXXmed

XTRA:T5O

€673.0k

4SC

DB:VSC

€42.2m

Price History & Performance

Summary of share price highs, lows and changes for Deutsche Biotech Innovativ
Historical stock prices
Current Share Price	€5.05
52 Week High	€34.40
52 Week Low	€5.00
Beta	0.34
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-79.80%
3 Year Change	-92.89%
5 Year Change	-92.84%
Change since IPO	-34.84%

Recent News & Updates

Recent updates

Shareholder Returns

	DBI	DE Biotechs	DE Market
7D	0%	-2.5%	-2.6%
1Y	-79.8%	-14.2%	7.1%

Return vs Industry: DBI underperformed the German Biotechs industry which returned -22.1% over the past year.

Return vs Market: DBI underperformed the German Market which returned 9.5% over the past year.

Price Volatility

Is DBI's price volatile compared to industry and market?
DBI volatility
DBI Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: DBI has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DBI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	1	Bernd Wegener	www.dbi-ag.de

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.

Deutsche Biotech Innovativ AG Fundamentals Summary

How do Deutsche Biotech Innovativ's earnings and revenue compare to its market cap?
DBI fundamental statistics
Market cap	€4.55m
Earnings (TTM)	-€236.44k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-19.2x

P/E Ratio

Is DBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBI income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€236.44k
Earnings	-€236.44k

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.25
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did DBI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/24 00:16
End of Day Share Price	2023/09/26 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Deutsche Biotech Innovativ AG is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Simon Scholes	First Berlin Equity Research GmbH